DPYD and colorectal cancer: The aim of the present study is to elucidate the clinical role of the DPYD rs4294451 variant as predictive pharmacogenetic markers of the clinical outcome (severe toxicity and prognosis) related to an FL-based treatment in a cohort of 645 patients with colorectal cancer (CRC).